MedTrace Logo

Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

NCT06695013 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2025-01-24

No results posted yet for this study

Summary

This study aims to explore whether adding immunotherapy bridging treatment for low-risk refractory/relapsed B-NHL can demonstrate better outcomes, in order to find the most effective treatment plan for low-risk patients.

Conditions

  • B-NHL
  • CART Therapy

Interventions

DRUG

zanubrutinib

zanubrutinib 160 mg BID orally

DRUG

CAR-T

CAR-T Cell therapy

RADIATION

Bridging radiotherapy

For patients in the experimental group, the decision regarding radiotherapy will depend on whether the specific lesions are suitable.

DRUG

Tislelizumab

200mg IV Q3-4W

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-20
Primary Completion
2026-11-20
Completion
2027-03-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06695013 on ClinicalTrials.gov